



aMoon 2020 Impact Report

Accelerating Cure

We are excited to share the first in what we expect will be an annual series of aMoon Impact reports. The purpose of this annual Impact Report is to share the progress our portfolio companies are making as they move along the path from innovation to commercialization to societal impact.

Table of Contents

03

AT A GLANCE

04

OUR MISSION

08

OUR IMPACT

13

COMPANY SPOTLIGHTS

AT A GLANCE

2017

FOUNDED

\$1.3B

AUM

53

TEAM MEMBERS

42

PORTFOLIO COMPANIES

6

PUBLIC COMPANIES

8

2020 NEW INVESTMENTS

MEDICAL AREAS



15

BIOPHARMA



8

DIGITAL HEALTH



10

MEDTECH



9

TOOLS & DIAGNOSTICS

INVESTMENT THEMES



- 51% Personalized & paradigm-shifting treatments
- 31% Engineering biology-powered hardware, computer science and engineering to tackle complex biological problems
- 18% The convergence of Big Data and AI-leveraging software, through its predictive power, to triage and diagnose patients

FUNDS



aMoon Growth

Invests in later-stage companies in growth rounds, pre-IPO rounds or in pivotal clinical trials




aMoon Velocity

Invests in companies pursuing disruptive, cutting-edge technologies as early as venture formation through seed/round A

OUR MISSION

Accelerating Cure.



aMOON'S MISSION

aMoon was founded in 2017 to seize on the rapid convergence of healthcare and technology with the mission to Accelerate Cure. We have been built from the ground-up with this goal in mind. By partnering with outstanding entrepreneurs, management teams in Israel, and other global centers of innovation, we push ourselves to advance solutions that will help people live healthier, longer, and better lives. While our mission is first and foremost about cures, we recognize that the element of time is also critical and we view ourselves as agents to help bring revolutionary ideas to life – quickly.

WHAT ARE WE SOLVING FOR?

The convergence of healthcare and technology is creating remarkable potential to confront the most pressing challenges facing modern day health systems: how to break through the iron triangle – to simultaneously improve access to care, quality of care and cost of care to Accelerate Cure.

Solving for Health

Over the past decade we have witnessed remarkable scientific breakthroughs and advancements that have prolonged life and improved quality of life for those with access to care. COVID-19, while wreaking havoc across the globe, is proving out the “HealthTech Effect.” Ten years ago, no one would have dreamed of being able to sequence the SARS cov-2 (and variant) genomes instantaneously at a cost of a few hundred dollars. mRNA technology was in its infancy, nowhere near ready to produce a vaccine in a matter of months.

Integrated electronic records enabled both the identification of high risk COVID-19 patient groups, the effective rollout of massive vaccination operations such as Israel's.

COVID-19 also accelerated major HealthTech trends, moving healthcare away from the hospital to the community and home and turning virtual into the new normal. The basic infrastructure to enable remote care for patients was also embryonic. While these and other HealthTech advances over the past decade are indeed remarkable, they are not enough. Access to high quality care is still sorely lacking in many geographies and healthcare costs continue to outpace GDP growth (US healthcare costs grew by 4.6%, double the rate of GDP growth). We are still in the very early stages of the HealthTech revolution and there is still so much work to advance solutions that will help people live healthier, better lives.

Solving for Economic Growth

A year into the global pandemic, as the effects of COVID-19 continue to unfold around the world, we have witnessed an unprecedented acceleration of the digital convergence of healthcare and technology.

While COVID-19 created a global economic crisis for countless industries, it has also created major disruption and growth opportunities. COVID-19 stimulated tectonic shifts in the Healthcare industry, fueling a rapid and large-scale HealthTech movement, and the growth of a global economic engine.

The HealthTech industry will continue to grow, and its burgeoning technologies are poised to create economic growth engines for nations around the globe, facilitate the growth of pioneering companies, generate high-paying jobs, and leverage this momentum to improve healthcare systems' efficiency and reduce healthcare costs.

17.7%

U.S. HEALTHCARE SPENDING AS
PERCENTAGE OF GDP

39%

OF ALL NEW DRUGS APPROVED BY THE
FDA IN 2020 WERE PRECISION MEDICINE
DRUGS

11

MONTHS FROM SEQUENCING THE SARS-
COV-2 GENOME TO FDA APPROVED
VACCINE

WHERE IS HEALTHTECH HEADING?

Looking ahead, we are committed to supporting the HealthTech movement's shift away from high cost, reactive care delivery towards predictive and preventative care that stratifies, flags, and performs proactive outreach to high-risk populations. This change will enable a shift of care away from high-cost treatment centers such as ERs and hospitals towards less expensive care models in the home and the community. We also believe that significant reductions in the cost of genomic sequencing, the advent of multi-omic technologies and huge improvements in bio-informatics capabilities will allow for less invasive screening of disease at earlier

stages. To provide proactive, not just reactive care. To prevent, not only to treat.


Healthcare's digital convergence will continue to transform the entire life science ecosystem. It will offer enhanced capability to more efficiently identify drug targets, and conduct drug discovery and development." We are also at the dawn of an era where implantable devices, communicating with mobile devices and the cloud, will offer better ability to predict chronic disease and analyze and communicate relevant anticipatory clinical data to physicians.

The Multi-Omics Revolution: Deciphering Humanity’s Barcode

We’re at the verge of a scientific revolution that is driving the next great leap forward in understanding our individual biology and transforming human health. As the genome revolution marked the beginning of a new era, Omics science is unveiling fundamentally new possibilities to unlock new biological information and enable a limitless breadth

and depth of data and scientific insights that will reshape the way we diagnose, prevent, treat, and cure disease.

Omics science fuels the shift from traditional, reactive diagnostics and one size fits all treatment to a holistic perspective of preventative early diagnostics and personalized therapeutics.



MULTI-OMICS

Multi-omics relates to the integration of diverse omics data, many times collected from the same biological sample, to reveal novel interactions and associations between biological entities and to discover new bio markers of disease.



GENOMICS

The genome is the complete sequence of DNA in a cell or organism. Decoding human genes and their interactions with each other.



TRANSCRIPTOMICS

The transcriptome is the complete set of RNA transcripts from DNA in a cell or tissue. Revealing the extent to which each gene is activated or deactivated.



PROTEOMICS

The proteome is the complete set of proteins expressed by a cell, tissue, or organism. Detecting protein expression.



METABOLOMICS

The metabolome is the complete set of small molecule metabolites found within a cell, tissue or organism [biological sample]. Measuring the dynamics of metabolic response (small molecule substrates).



Multi-omics technologies are greater than the sum of their parts, enabling molecular profiling and integration of multi-omics data to simultaneously study genes, RNA, proteins and metabolites and reveal the interaction networks at the molecular levels. These emerging groundbreaking technologies provide high resolution and accuracy to decipher cellular and molecular mechanisms, and to understand individual gene expression, biological processes and disease.

The impact of life sciences companies at the forefront of the Omics revolution cuts across the healthcare value chain and is revolutionizing delivery of patient care:

Discover

Transforming the foundations of scientific research to enable the discovery and development of new approaches to medicine.


Diagnose

Creating new ways to understand and diagnose diseases on time.

Treat

Producing precision and personalized therapeutics and delivering them in new ways to patients.

New breakthrough technologies will enable the revelation of never-before-seen molecular information at unprecedented resolution and accuracy, leading to valuable insights for individual health.



OUR IMPACT

Harvesting a deep blue ocean of innovation to revolutionize healthcare.

WHY IMPACT MATTERS?

First, because it is part of our DNA. What drives us as individuals and as an organization is the desire to make a difference. Ultimately we are looking to increase longevity and improve people's quality of life by partnering with companies that Accelerate Cure. As investors our goal is to produce exceptional returns for our LPs. However, what makes us different is that we don't look at financial returns in isolation, but rather as the natural product of an investment in a company that is successful at solving healthcare's greatest challenges. This is what creates sustainable value and makes aMoon's mission inherently impactful.

Second, because our focus on impact allows us to form a common language with our partners and stakeholders. When we connect with scientists,


physicians, and entrepreneurs we do so through the language of science, healthcare outcomes, quality and efficiency. This common language is what connects us more deeply to the key innovators in healthcare value chain. And when we do that, we become better informed – we run smarter diligence processes and find more ways to add value to our portfolio companies – in short, we become better investors.


Finally, we believe that most, if not all, of our LPs care deeply about achieving multiple objectives – accelerating cure, generating excellent financial returns and having societal impact. By aligning across these elements it helps us to develop a stronger relationship with our limited partners and be more thoughtful with our communication.

HOW WE THINK ABOUT & MEASURE IMPACT?

We think about impact in several ways. First, impact has to be measurable and easy to understand. Second, it has to be connected to a larger mission and resonate with stakeholders. Third, it needs to move from the macro to the micro and 'meet the individual' by touching lives.

In venture capital, we believe that impact needs to be measured in three phases –innovation, commercialization, and scale. We start our analysis of impact by looking at the end result, societal Impact, what we call scale. When we think about scale, we are interested in measuring substantial impact on longevity and quality of life, scientific progression and better healthcare delivery, alongside substantial value for stakeholders.





Our impact assessment manifests across the entire investment cycle; from screening, through investing to monitoring our portfolio. We have defined six impact pillars that derive from our mission to accelerate cure.

Save & extend lives

Save life or meaningfully extend life: innovations that can cure diseases and save lives through breakthrough treatments.

Paradigm shifting breakthroughs

Enabling the development of groundbreaking technologies transforming the way we diagnose and treat severe disease.

Improve quality of life

Improve the quality of life for those with chronic diseases: treatments for some of the most challenging unmet needs.

Access to healthcare

Better access to healthcare: we back cutting-edge technologies to democratize healthcare and ensure access to affordable, quality health services for all.

Reduce costs

Reduce healthcare costs: as healthcare costs rise to unsustainable levels we focus on increasing institutions' capacity and cutting costs.

Predictive & personalized medicine

Promote predictive and personalized medicine, and new ways of delivering healthcare: from reactive to predictive, from treatment to prevention, from generic to personalized.

aMOON'S INNOVATION INDEX

Company	Description	Save & extend lives	Paradigm shifting breakthroughs	Improve quality of life	Access to healthcare	Reduce costs	Predictive & personalized medicine	Impact stage
seer	Capturing first-ever generation of proteomic information to empower the scientific community and significantly advance our understanding of biology, health, and disease.		●				●	1 2 3 4
Adicet Bio	Developing cutting-edge Universal off-the-shelf T cell therapy for cancer and other diseases by harnessing the power of the immune system.	●	●	●		●		1 2 3 4
STEALTH	Advancing the development of personalized medicine in collaboration with academic centers of excellence.		●			●	●	1 2 3 4

aMOON'S INNOVATION INDEX

Company	Description	Save & extend lives	Paradigm shifting breakthroughs	Improve quality of life	Access to healthcare	Reduce costs	Predictive & personalized medicine	Impact stage
 aya:a	Developing targeted cancer therapies for genetically defined, clinically underserved cancers.	●						1 2 3 4
 VIRACTA	Advancing a proprietary viral gene activation therapy to benefit patients with virus associated cancers and other serious diseases.	●	●				●	1 2 3 4
 CartiHeal	Developing a cell-free, off-the-shelf implant for the treatment of cartilage and bone defects.			●		●		1 2 3 4
 SOPHiA™	Established the world's largest Data-Driven Medicine community network to unlock the power of genomics data for cancer and rare disease management.		●	●			●	1 2 3 4
 prognomiQ	Developing multi-omics simple blood tests for early detection of cancer and other complex diseases.	●	●			●	●	1 2 3 4
 MDCLONE	Developed a solution that centralizes data from siloed sources to enable data-driven healthcare exploration, discovery and delivery.		●					1 2 3 4
 MOBILion SYSTEMS, INC.	Developing and commercializing best-in-class, high-resolution/high-speed analytical instruments to accelerate biologic drug development and biomarker discovery.		●				●	1 2 3 4
 DAY TWO	Offering personalized nutrition and therapeutic solutions to prevent and treat metabolic diseases by leveraging advanced genetic sequencing of gut microbiome and big data analytics.						●	1 2 3 4
 satellite BIO	Developing proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions for million of patients suffering from organ failure diseases.	●	●	●				1 2 3 4
 MINA Therapeutics	Enabling the development of new saRNA medicines to transform the therapy landscape in cancer and other diseases.	●	●					1 2 3 4
 IBEX	Developed an AI-based system for cancer diagnostics in Pathology improving diagnosis accuracy and increasing pathology labs productivity and efficiency.	●				●	●	1 2 3 4
 scipher MEDICINE	Developing a first-of-its kind blood based molecular test identifies a patient's unique disease biology to determine which drug actually targets the disease, allowing to make the right therapy decision.	●	●			●	●	1 2 3 4
 METASIGHT DIAGNOSTICS	Developed Next Generation Metabolomics/Lipidomics technologies allowing full metabolic profiles analyses to generate early diagnostic biomarkers for various diseases.					●	●	1 2 3 4
 zebra	Developed an AI-based radiology imaging analytics platform to improve patient care by identifying risks earlier, facilitate disease prevention, optimize prioritization and reduce cost of care.	●			●	●	●	1 2 3 4
 NECTNTx	Developing next generation cancer immuno-therapeutics targeting novel immune checkpoint pathways for the treatment of solid and hematological malignancies.	●	●					1 2 3 4


aMOON'S INNOVATION INDEX

Company	Description	Save & extend lives	Paradigm shifting breakthroughs	Improve quality of life	Access to healthcare	Reduce costs	Predictive & personalized medicine	Impact stage
LIN HEALTH	a digital remote pain care clinic, managing patients throughout their pain treatment journey.			●	●			1 2 3 4
 BioLogicDesign	Developing a new tool to re-engineer human antibodies to create novel therapies for cancer and other diseases.	●						1 2 3 4
nanoGhōst	A synthetic biology company engineering next-generation cancer detection and treatment agents.	●	●			●		1 2 3 4
 ALTRUBIO	Developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs.	●	●					1 2 3 4
theranica	Developing a non-invasive, drug-free, personalized and affordable wearable therapeutic products migraines treatment.			●				1 2 3 4
VocalisHealth	Developing AI and voice analysis vocal biomarkers for remote diagnosing and monitoring of multitude health conditions from speech derived features.			●	●	●	●	1 2 3 4
igentify	Enabling an end-to-end digital personalized genetic testing and counseling services at scale.				●	●		1 2 3 4

Generating this degree of societal impact is predicated on achieving commercial success which, in turn, is driven by great product market fit, market access and relentless execution. As a young investment platform, most of our companies are still in the pre-commercial stage and over time they will advance to the commercialization and scale phases.

IMPACT STAGE

- 1 Early Development
- 2 Late Development
- 3 Early Commercialization
- 4 Late Commercialization



INNOVATION

- Clinical programs
- Scientific collaborations
- Scientific breakthroughs



COMMERCIALIZATION

- Product approvals / launches
- Treatments administered
- Revenues generated



SCALE

- Lives saved / meaningfully extended
- Quality of life metrics
- Costs saved

To measure innovation we look at indicators such as active clinical programs, quality of academic collaborations and size of R&D investments.

On the commercialization front, besides analyzing metrics such as units sold and revenues, we also look at indicators such as number of approvals, number of innovative products launched, number of treatments/tests administered.

On the scale front, we look through two lenses: 1) Breadth - how scalable is the solution and how many people and lives can we touch?

And 2) Depth - how fundamental and deep is the impact? We look at measures such as survival improvements and improved disease control rates for those living with chronic diseases. We will also look to measure the impact our portfolio companies are having in terms of promoting predictive and personalized medicine. Finally, we will attempt to quantify how our portfolio companies are succeeding in reducing healthcare costs and improving efficiency of care delivery as well as provide some macroeconomic perspectives on measures such as the number of jobs created and market value created.

ACCELERATING SCALE

IN 2020 WE SUPPORTED:

33

COMPANIES

Strategic analysis, prioritization and planning

19

COMPANIES

Business development: partnerships, customers, new markets

27

COMPANIES

Financing strategy & fundraising

26

COMPANIES

Talent hunting & placement

15

COMPANIES

Positioning, marketing, PR and storytelling

Magnifying our impact by supporting our portfolio companies

We focus on impact both on the portfolio level and the investor level. As an investor, we have an enormous opportunity to enhance our portfolio’s impact by adding value and accelerating our portfolio’s growth as early as the diligence process all the way through the investment and value creation journey.

aMoon Alpha is our in-house team dedicated to strengthening our portfolio company’s execution capabilities and unlocking additional value creation opportunities. Through Alpha, we tap aMoon’s global network and talent capabilities to offer our portfolio companies tailored access to global capital markets, leading research and scientific institutions, strategic collaborators, and customers. aMoon Alpha, together with our investment teams, equips entrepreneurs with the expertise, networks, connections, resources, and support they need to accelerate their path to value creation so they can build world-leading companies.

Company Spotlights



theranica

Date Invested: **March 2019**
Sector: **Medtech**
Stage: **Early Commercialization**

100K

Migraines treated

1B+

Worldwide suffer from migraines



Nerivio is a life-changing treatment. Nerivio is not a want – it's a need. This safe treatment for migraines is a vital break-through for my patients' quality of life. It's my responsibility to let colleagues and patients know about this important therapy.

Dr. Kathy Fields

Migraines are one of the most prevalent and disabling neurologic diseases, disproportionately affecting women. Migraine attacks are frequently treated symptomatically with prescription medications which are often poorly tolerated, contraindicated, and if used excessively, may lead to significant medical complications, including medication overuse headache.

Theranica has developed Nerivio™, an FDA authorized easy-to-use, non-invasive, safe and non-chemical wearable device for the acute treatment of migraine. The wearable, Nerivio™, is applied to the upper arm and activated by a smartphone app which begins a 30-40 minute session that stimulates endogenous pain inhibitory mechanisms in the brain through electrical neuromodulation. Results from numerous large-scale clinical studies show efficacy results as good as the gold standard pharmacological treatments with a stronger safety profile of minimal side effects.



DAY TWO

Date Invested: **January 2017**
Sector: **Digital Health**
Stage: **Early Commercialization**

62K

Gut microbiomes sequenced, and personalized diets delivered

422M

People worldwide suffer from diabetes




When I started with DayTwo I was taking medications for diabetes and my thyroid. After 4 months of using the recommendations, my HbA1c, glucose, and TSH went down significantly. Since starting DayTwo, I can eat what I like as long as it is in the right combination and don't feel hungry or frustrated.

Limor G, DayTwo Patient

DayTwo is a diabetes solution platform based on Microbiome Precision Medicine. The Company offers personalized nutrition solutions using artificial intelligence and machine learning. The Company leverages its Gut Microbiome Platform™ to conduct advanced genetic sequencing of an individual's gut microbiome.

Based on research out of the Weizmann Institute, DayTwo has shown that an individual's glucose response to food is highly personalized and is not solely determined by the glycemic index of a particular food. Combining an individual's gut microbiome sequencing data with big data analytics allows us to more accurately predict an individual's glycemic response to specific foods. DayTwo translates this data into personalized, actionable dietary recommendations and modifications primarily aimed at preventing and treating metabolic diseases such as diabetes and obesity. Clinical data has shown an ability to drive clinically meaningful reductions in HbA1C and weight.



IBEX

Date Invested: **March 2019**
Sector: **Digital Health**
Stage: **Early Commercialization**

40%


Improved efficiency of pathology lab when deploying Ibex's technology

2M

New breast cancer cases each year worldwide

Pathologists are becoming an increasingly scarce resource worldwide. Combined with the significant rise of cancer cases, the workload of US pathologists increased by ~50% over the past decade. This causes pathologists to spend less time on each case, leading to higher rates of diagnostic errors, which directly and adversely impact patients' treatment and health and increase costs for the healthcare system. Pathology services, therefore, need to adapt in order to meet the demands of the healthcare system. This means bringing cutting-edge technology into the laboratories to make the system as agile, efficient, and accurate as possible.

Ibex Medical Analytics is a pioneer in AI-powered cancer diagnostics in pathology. Ibex uses artificial intelligence (AI) to develop clinical-grade solutions that help diagnose cancer with unprecedented accuracy and speed. Ibex combines data from pathology glass slides and electronic medical records obtained through exclusive access to Maccabi Healthcare to reveal underlying patterns and extract valuable clinical insights that can transform how pathology and oncology are practiced and propel them into the information age. Ibex's Galen Platform uses algorithms to analyze images, detect and grade cancer in biopsies and point to other findings of high clinical importance, helping pathologists reduce diagnostic error rates, significantly decrease turn around time and enable a more efficient workflow. Deployed worldwide, Ibex's Galen™ Prostate and Galen™ Breast are the first-ever AI-based cancer detection solutions used in routine clinical practice in pathology labs, with demonstrated success in detecting missed cancer cases.



MDCLONE

Date Invested: **August 2019**
Sector: **Digital Health**
Stage: **Early Commercialization**

50M+

Patient data available as synthetic in global network

50+

Start-ups collaborating with health systems


“

The only way to stay in this business for 25 years and still wake up every morning and do the job is because you believe in the values and when you see value in what you do.

Ziv Ofek, MDClone Founder & CEO

Navigating data in a health system can be challenging, expensive, and time-consuming. Answering even simple questions can take months or longer due to siloed IT systems, complex data models, unstructured data, privacy regulations, and ultimately, limited bandwidth from IT staff.

MDClone has introduced a groundbreaking solution for data-driven healthcare exploration, discovery and delivery. MDClone provides the tools – and the underlying technology – to integrate healthcare data from disparate sources and provide never-before-possible clinical and operational insights to improve and ultimately share best practices in care delivery in a very timely manner, without compromising patient privacy. The platform is based on MDClone's proprietary data engine and synthetic technology. Any question, cohort or population and any data element from any source can be analyzed, all in familiar terminologies without programming skills or mediators, and all with zero-risk to patient privacy.



Date Invested: **August 2020**

Sector: **Tools & Diagnostics**

Stage: **Early Development**

84%

of lung cancer cases are diagnosed at a late stage

49%

Increase in the lung cancer survival rate with an early diagnosis


“

We embarked on this journey to enable early detection, treatment, and recurrence monitoring of cancer and other complex diseases.

Philip Ma, Ph.D., PrognomiQ CEO

There is a large unmet need for improved tests that will allow for earlier detection, treatment and recurrence monitoring of disease. The understanding of biology has advanced tremendously through large-scale genomic data collection capabilities. Yet, despite these advancements, researchers and clinicians do not have the functional context at the protein level to support early disease detection and prevention.

PrognomiQ is a diagnostics company developing a simple blood test for early detection of cancer and other complex diseases. As a spinout company from Seer, an aMoon Growth portfolio company, PrognomiQ leverages Seer's Proteograph technology for unbiased proteomic analysis at unprecedented depth, breadth, and scale. PrognomiQ will combine this unique proteomics data from the Proteograph, with genomics and other omics data, to develop and commercialize multi-omics tests for cancer and other complex diseases. Their differentiated multi-omics approach will lead to better diagnostics solutions and put the genetic variation in disease in a functional context.



Date Invested: **November 2020**

Sector: **BioPharma**

Stage: **Early Development**

500M

Liver disease patients worldwide

Liver disease accounts for approximately 2 million deaths per year worldwide and represents a major global burden and unmet therapeutic need. Whole and partial liver transplants are the gold standard solutions for liver disease, but persistent donor organ shortage limits the efficacy of liver transplants. Liver cell therapies, such as Hepatocyte cell transplantations, have achieved functional rescue but failed long-term therapeutic effect.

Satellite is developing first-in-class, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases. Building on 25 years of work in award-winning labs at MIT, Harvard, Penn, and BU, the platform is supported by a strong IP portfolio and clinical proof of concept.



Date Invested: **September 2020**

Sector: **Digital Health**

Stage: **Late Commercialization**

1,000+

Hospitals worldwide

600k+

Genomic profiles analyzed

“

The mission of SOPHiA genetics is to improve the life of patients by providing clinicians with faster and more precise diagnostics for better treatment options to do so we've developed SOPHiA a cutting-edge collective artificial intelligence which helps clinicians make sense of their patient's genomic data.

Jurgy Camblong, SOPHiA CEO & Co-founder

As more personal health data is being collected at scale, an urgent need arises for its accurate and accessible interpretation to unlock the value of personalized medicine. SOPHiA strives to develop solutions that can be used in a decentralized manner, not bound by physical location or type of data structure, and that not only accurately and rapidly analyze the data, but also help derive clinical insights to integrate with treatment decisions and drug development. Combining the first two pillars of Data-Driven Medicine, Genomics and Radiomics, SOPHiA ensures that the data used to help patients today will also benefit the patients of tomorrow.

The company has developed a leading cloud-based AI platform that provides genomic data analysis to genomic labs and clinicians, offering end-to-end, customized solutions for efficient assessment of complex variants associated with various diseases. SOPHiA AI leverages statistical inference, pattern recognition and machine learning to maximize the value of genomics and radiomics data, offering a platform that enables a decentralized solution for broad scale genetic analysis. By unlocking the power of new-generation health data for cancer and rare disease management, the universal SOPHiA Platform allows clinical researchers to act with precision and confidence. The company's innovative approach enables experts from hundreds of healthcare institutions to benefit from sharing their knowledge and experience, fostering a new era in healthcare.



Date Invested: **January 2017**

Sector: **MedTech**

Stage: **Late Commercialization**

100K

Patients worldwide

600K

knee replacement surgeries in the U.S. every year

“

I've had knee problems for a couple years now. The mental part of this injury has been more severe for me than the physical part of it. The first day that I came in here and I put these on, I cried. Because I could move, and I could walk like a normal person again.

Robert LaSalle, AposHealth Patient

Chronic knee pain is a growing concern in the U.S. and globally, as the rate of knee replacement surgeries continues to rise.

Total knee replacement for patients suffering from advanced knee osteoarthritis is an invasive and costly procedure and considered as the last resort following traditional treatment and physical therapy. Furthermore, musculoskeletal pathologies of the knees and lower back, which is characterized by an increased load on the problematic areas and poor muscle control, can cause pain and difficulty in performing daily activities such as walking.

While medicines and injections address the sensation of pain and can turn off patients' inflammation and pain sensations temporarily, AposHealth takes a different approach by realigning the body and helping improve muscular control and coordination – thereby relieving pain and significantly improving daily function.

AposHealth is a clinically proven, FDA cleared solution for knee and lower back pain—without the need for surgery, injections, opioids or a dramatic change in patients' daily routine. AposTherapy's drug-free, at-home treatment addresses the root cause of the pain by shifting the pressure from the painful area and by re-educating the muscles for a healthier walking pattern, and it is the only effective alternative to knee replacement at a fraction of the cost.